Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
March 24, 2023 Off

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

By GlobeNewswire

RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eyeREDWOOD…

March 24, 2023 Off

Aptose Reports Results for the Fourth Quarter and Full Year 2022

By GlobeNewswire

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of…

March 24, 2023 Off

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

By GlobeNewswire

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of…

March 24, 2023 Off

Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit

By GlobeNewswire

CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) —  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…

March 24, 2023 Off

DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

By GlobeNewswire

SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a…

March 24, 2023 Off

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

By GlobeNewswire

– Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout…

March 24, 2023 Off

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

By GlobeNewswire

On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline…

March 24, 2023 Off

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

By GlobeNewswire

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y…

March 24, 2023 Off

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

By GlobeNewswire

Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approvalGARDEN CITY, N.Y.,…

March 24, 2023 Off

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

By GlobeNewswire

Management to host conference call and webcast at 4:30 p.m. ETIRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals,…

Posts navigation

Previous 1 2 3 … 4,737 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update

March 25, 2023 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off
Proudly powered by WordPress | Theme: Envo Magazine